Comprehensive overview

The Group is a vaccine company founded in 2012, focusing on the research and development of HPV vaccine candidates. The Group has established a vaccine portfolio of 12 candidate vaccines, including the core product REC603, a recombinant HPV nine-valent vaccine for the prevention of cervical cancer, which is currently in phase III clinical trials.

According to Frost Sullivan, in terms of the total population, the overall coverage rate of HPV vaccine in China was generally low, less than 1 per cent, by the end of 2020.

Risk factors.

The Group is a clinical biotechnology company. As of the latest practicable date, the Group has not successfully conducted any commercial sale of candidate vaccines, nor has it generated any revenue from vaccine sales. However, the Group has incurred significant expenditure on the research and development of candidate vaccines and has suffered significant net losses since its inception and is expected to continue to incur net losses in the foreseeable future and may not be able to achieve or maintain profits.